Japan Atopic Dermatitis Therapeutics Market Report 2022 to 2030

Japan Atopic Dermatitis Therapeutics Market Analysis

$ 3999

The Japan Atopic Dermatitis Therapeutics Market was valued at US $77 Mn in 2022, and is predicted to grow at (CAGR) of 9.3% from 2023 to 2030, to US $1.56 Bn by 2030. The key drivers of this industry include the increasing disease burden of Atopic Dermatitis (AD), growing healthcare spending, and an evolving treatment landscape. The industry is primarily dominated by players such as Otsuka, Maruho, Tanabe, Fuji Film, Sanofi, Novartis, Mitsubishi, and AbbVie, among others.

ID: IN10JPPH435 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Riddhi Solanki

Buy Now

Japan Atopic Dermatitis Therapeutics Market Analysis: Executive Summary

The Japan Atopic Dermatitis Therapeutics Market is at around US $0.77 Bn in 2022 and is projected to reach US $1.56 Bn in 2030, exhibiting a CAGR of 9.3% during the forecast period.

Atopic dermatitis, commonly known as eczema, is a persistent skin condition characterized by inflammation, redness, and irritation. It is non-contagious and can affect individuals of all age groups, with a higher prevalence often observed in childhood. Key risk factors include a personal or familial history of eczema, allergies, hay fever, or asthma. Common symptoms include intense itching, redness, swelling, cracking, clear fluid discharge, crusting, and scaling. Approaches to managing atopic dermatitis may involve regular moisturizing and self-care practices, the application of medicated creams to alleviate itching and support skin repair, the use of topical or oral medications, and additional therapies such as phototherapy or immunosuppressants. Several companies, including Sanofi, Pfizer, AbbVie, Leo Pharma, Eli Lilly, and Teva Pharmaceutical, provide therapeutic options for atopic dermatitis, encompassing topical corticosteroids, calcineurin inhibitors, and other medications designed to alleviate the symptoms of the condition.

Japan is one of the leading countries in the prevalence of AD, with estimates suggesting a prevalence ranging between 10–20% in children and 2–5% in Japanese adults. The market is being driven by significant factors such as the increasing disease burden, growing healthcare spending, and evolving treatment landscape in the therapeutics market. However, conditions such as limited affordability, regulatory hurdles, and health system challenges limit the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Increasing AD burden: Japan experiences one of the highest prevalence rates of atopic dermatitis (AD) worldwide, impacting approximately 10–20% of children and 2–5% of adults. As the population ages and life expectancy increases, the number of individuals prone to chronic skin conditions like AD is anticipated to grow. Environmental factors such as pollution, stress, and dietary changes linked to urbanization are associated with an increased incidence of AD.

Increased government spending: Japan maintains a substantial investment to healthcare, with per capita spending reaching US $4665 in 2020. This enduring investment fosters innovation and accessibility within the AD therapeutics market. A strong private healthcare insurance system ensures broader access to advanced treatments, including biologics. Increasing living standards empower patients and their families to afford newer and more expensive options for AD treatment.

Emerging treatment landscape: The advent of innovative biologics and targeted therapies with enhanced effectiveness and fewer side effects, introduced by pharmaceutical companies like Otsuka, is transforming the landscape of AD treatment. The progress in creating advanced drug delivery systems, such as topical foams and sprays, enhances medication adherence and improves patient comfort. Breakthroughs in genetic testing and biomarkers are laying the foundation for personalized treatment approaches tailored to the specific needs of individual patients.

Market Restraints

Limited affordability: Imported medications, especially recent biologics, come with high costs attributed to research and development expenses, limited competition, and import tariffs. Consequently, a considerable portion of the population finds them largely unaffordable. Despite Japan having universal healthcare, obtaining coverage for AD treatments like biologics often necessitates extensive documentation and justification, resulting in potential delays and denials.

Health system challenges: Despite being a prominent medical nation, Japan encounters a shortage of dermatologists, particularly in rural areas, which constrains access to specialized care for AD patients. Rural areas frequently lack specialized dermatologists and advanced treatment facilities, leading to disparities in access to high-quality care.

Regulatory hurdles: Thorough safety and efficacy assessments can lead to delays in introducing innovative AD treatments in Japan, as compared to other developed markets. Government-imposed price controls and fixed reimbursement rates for specific medications may not accurately represent their actual cost or value, which might discourage pharmaceutical companies from entering the market.

Notable Updates

August 2022, Maruho Co Ltd by Chugai Pharmaceuticals has introduced the Anti-IL-31 Receptor A Humanized Monoclonal Antibody Mitchga in Japan for the management of itching related to AD.

June 2022, Otsuka Pharmaceutical Co., Ltd. has reported the approval of a novel atopic dermatitis treatment, Moizerto® Ointment, available in 1 percent and 0.3 percent formulations, in Japan.

Healthcare Policies and Regulatory Landscape

Japan's healthcare regulatory landscape is overseen by the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour, and Welfare (MHLW). The PMDA is a regulatory body responsible for evaluating and approving pharmaceuticals and medical devices in Japan. The MHLW sets broader healthcare policies and regulations. The regulatory process in Japan is known for its meticulous and stringent standards to ensure the safety and efficacy of pharmaceutical products.

Obtaining a license for a new drug in Japan involves a comprehensive submission to the PMDA, including detailed data on the drug's clinical trials, safety profile, and manufacturing processes. The approval process typically includes a thorough review and consultation with experts to assess the product's suitability for the Japanese market.

For new entrants, the Japanese pharmaceutical market presents both opportunities and challenges. While Japan represents a significant market with a high demand for innovative healthcare products, the regulatory environment can be complex. New entrants must navigate the intricacies of Japanese regulations, including the Pharmaceutical Affairs Law, and work closely with the PMDA to gain approval for their products.

Competitive Landscape

Key Players

Otsuka Pharmaceutical
Maruho
Taisho Pharmaceutical
Kaken Pharmaceutical
Fuji Film Medical
Mitsubishi Tanae Pharma
Sanofi
Novartis
AbbVie
Leo Pharma

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Atopic Dermatitis Therapeutics Market Segmentation

By Drug Class

Corticosteroids
Calcineurin Inhibitors
Immunosuppressants
Biologic Therapy
PDE-4 Inhibitor
Antibiotics
Antihistamines
Emollients

By Route of Administration

Topic
Oral
Injectable

By Severity type

Mild
Moderate
Severe

By Age Group

18 years and below
19 years and above

By Distribution channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Dermatology Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.